Head of Investor Relations
Neurocrine Biosciences Inc (NBIX)Equibles does not estimate personal net worth.
Get an email with a short summary when Neurocrine Biosciences Inc publishes a filing, an earnings call transcript or a press release.
Get NBIX alertsTodd Tushla is recorded as Head of Investor Relations at Neurocrine Biosciences Inc (NBIX). Todd Tushla has spoken on 25 earnings calls and 1 other investor event across 1 company, most recently for Neurocrine Biosciences Inc on September 15, 2026. Neurocrine Biosciences Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Neurocrine Biosciences Inc includes Kevin Gorman (CEO and Board Member), Kyle Gano, Ph.D. (CEO and Board Member), Kyle W. Gano (CEO and Board Member) and 7 others.
“What I would say is, like you said, we're only six quarters in, and the launch has been great, but we're still learning a lot about the marketplace, learning a lot about the endocrinology community, the patients, where, when, and who they seek treatment from.”
“With me today on the call are Kyle Gano, Chief Executive Officer, Matt Abernathy, Chief Financial Officer, Eric Benevich, Chief Commercial Officer, Sanjay Kaswani, Chief Medical Officer, and in his well-deserved new role as Chief Business Officer, Samir Sadanti.”
“Joining me today are Kyle Gano, Chief Executive Officer, Matt Abernathy, Chief Financial Officer, Eric Benevich, Chief Commercial Officer, Sanjay Kaswani, Chief Medical Officer, and Samir Sadanti, Vice President of Strategy and Corporate Development.”
“Happy Wednesday to everyone, and welcome to Neurocrin Biosciences' fourth quarter and 2025 year-end earnings call.”
“I'm joined today by Kyle Gano, Chief Executive Officer; Matt Abernethy, Chief Financial Officer; Eric Benevich, Chief Commercial Officer; and Sanjay Keswani, Chief Medical Officer.”
Drug Manufacturers - Specialty & Generic · Healthcare
Head of Investor Relations
